RxDoctor Payments Data

Luis Arango, MD

Internal Medicine · Mission, TXNPI 1407877046

Payments from drug & device makers

$4,962in general payments, 2019–2025

Across 329 payments — averaging $15.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$764
  • Pfizer$744
  • Lilly USA, LLC$557
  • Novo Nordisk$505
  • GSK$432
  • AbbVie$358
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$4,79697%
  • Education$1673%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,962 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$10,859
Medicare patients
46
Services billed
151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate17$68,767
FarxigaDapagliflozin Propanediol94$58,496
OzempicSemaglutide43$49,235
EliquisApixaban113$41,438
JardianceEmpagliflozin46$34,421
JanuviaSitagliptin Phosphate34$29,799
TrulicityDulaglutide16$21,092
MyrbetriqMirabegron45$19,147
ProliaDenosumab11$18,756
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$17,778
TradjentaLinagliptin47$11,790
XareltoRivaroxaban14$10,982
Memantine Hcl214$10,570
Tresiba Flextouch U-100Insulin Degludec41$9,613
VascepaIcosapent Ethyl14$8,125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$764$58,49694 claims
Novo NordiskOzempic, Levemir$505$52,69955 claims
Boehringer IngelheimJardiance, Tradjenta$170$46,21193 claims
PfizerEliquis$744$41,438113 claims
MerckJanuvia$48$29,79934 claims
Lilly USA, LLCTrulicity, Olanzapine$557$22,39560 claims
Astellas Pharma US IncMyrbetriq$163$19,14745 claims
AmgenProlia$56$18,75611 claims
GSKTrelegy Ellipta$432$17,77829 claims
Johnson & JohnsonXarelto$75$10,98214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Mission

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →